GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Visioneering Technologies Inc (ASX:VTI) » Definitions » ROE %

Visioneering Technologies (ASX:VTI) ROE % : -72.32% (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Visioneering Technologies ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Visioneering Technologies's annualized net income for the quarter that ended in Jun. 2024 was A$-5.48 Mil. Visioneering Technologies's average Total Stockholders Equity over the quarter that ended in Jun. 2024 was A$7.57 Mil. Therefore, Visioneering Technologies's annualized ROE % for the quarter that ended in Jun. 2024 was -72.32%.

The historical rank and industry rank for Visioneering Technologies's ROE % or its related term are showing as below:

ASX:VTI' s ROE % Range Over the Past 10 Years
Min: -262.99   Med: -81.38   Max: -55.4
Current: -71.07

During the past 7 years, Visioneering Technologies's highest ROE % was -55.40%. The lowest was -262.99%. And the median was -81.38%.

ASX:VTI's ROE % is ranked worse than
81.67% of 802 companies
in the Medical Devices & Instruments industry
Industry Median: -0.21 vs ASX:VTI: -71.07

Visioneering Technologies ROE % Historical Data

The historical data trend for Visioneering Technologies's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Visioneering Technologies ROE % Chart

Visioneering Technologies Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -262.99 - -55.40 -74.25 -57.51

Visioneering Technologies Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -74.02 -81.92 -66.12 -64.02 -72.32

Competitive Comparison of Visioneering Technologies's ROE %

For the Medical Devices subindustry, Visioneering Technologies's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Visioneering Technologies's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Visioneering Technologies's ROE % distribution charts can be found below:

* The bar in red indicates where Visioneering Technologies's ROE % falls into.



Visioneering Technologies ROE % Calculation

Visioneering Technologies's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-5.156/( (9.328+8.602)/ 2 )
=-5.156/8.965
=-57.51 %

Visioneering Technologies's annualized ROE % for the quarter that ended in Jun. 2024 is calculated as

ROE %=Net Income (Q: Jun. 2024 )/( (Total Stockholders Equity (Q: Dec. 2023 )+Total Stockholders Equity (Q: Jun. 2024 ))/ count )
=-5.478/( (8.602+6.547)/ 2 )
=-5.478/7.5745
=-72.32 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Jun. 2024) net income data. ROE % is displayed in the 30-year financial page.


Visioneering Technologies  (ASX:VTI) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-5.478/7.5745
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-5.478 / 13.976)*(13.976 / 10.317)*(10.317 / 7.5745)
=Net Margin %*Asset Turnover*Equity Multiplier
=-39.2 %*1.3547*1.3621
=ROA %*Equity Multiplier
=-53.1 %*1.3621
=-72.32 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Jun. 2024 )
=Net Income/Total Stockholders Equity
=-5.478/7.5745
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-5.478 / -5.466) * (-5.466 / -5.668) * (-5.668 / 13.976) * (13.976 / 10.317) * (10.317 / 7.5745)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1.0022 * 0.9644 * -40.56 % * 1.3547 * 1.3621
=-72.32 %

Note: The net income data used here is two times the semi-annual (Jun. 2024) net income data. The Revenue data used here is two times the semi-annual (Jun. 2024) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Visioneering Technologies ROE % Related Terms

Thank you for viewing the detailed overview of Visioneering Technologies's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Visioneering Technologies Business Description

Traded in Other Exchanges
N/A
Address
30 Mansell Court, Suite 215, Alpharetta, GA, USA, 30076
Visioneering Technologies Inc is a medical device company. It designs, manufactures, sells, and distributes its NaturalVue daily disposable multifocal contact lenses for adults with Presbyopia and children with Myopia. The company offers NaturalVue MF contact lenses. Its Multifocal contact lens provides Presbyopia patients with near, intermediate, and distance vision, making it much easier for eye care professionals to fit their patients. It has two reportable segments; North America which includes its operations in the United States and Canada; and Europe/Asia Pacific which includes its operations outside North America.

Visioneering Technologies Headlines

From GuruFocus

Northstar Group, Inc. Buys 2, Sells 3 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-26-2023

Top 5 3rd Quarter Trades of Gibson Wealth Advisors LLC

By GuruFocus Research GuruFocus Editor 11-23-2022

Gleason Group, Inc. Goes on Buying Spree in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-11-2023

D'Orazio & Associates, Inc. Buys 3, Sells 2 in 4th Quarter

By GuruFocus Research GuruFocus Editor 01-26-2023

Top 5 3rd Quarter Trades of VISTA CAPITAL PARTNERS, INC.

By GuruFocus Research GuruFocus Editor 11-08-2022

Ellevest, Inc.'s Top 5 Buys of the 3rd Quarter

By GuruFocus Research GuruFocus Editor 11-02-2022

Top 5 4th Quarter Trades of Novo Holdings A/S

By GuruFocus Research GuruFocus Editor 02-18-2023

Top 5 3rd Quarter Trades of NISA INVESTMENT ADVISORS, LLC

By GuruFocus Research GuruFocus Editor 11-07-2022

Top 5 4th Quarter Trades of Flagship Private Wealth, LLC

By GuruFocus Research GuruFocus Editor 01-20-2023

Top 5 4th Quarter Trades of OPPENHEIMER ASSET MANAGEMENT INC.

By GuruFocus Research GuruFocus Editor 02-07-2023